CN111265528A - 法匹拉韦在治疗冠状病毒感染方面的应用 - Google Patents

法匹拉韦在治疗冠状病毒感染方面的应用 Download PDF

Info

Publication number: CN111265528A
Authority: CN; China
Prior art keywords: respiratory; sars; infections; coronavirus; acute respiratory
Prior art date: 2020-01-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN202010070142.0A

Other languages

English (en)

Chinese (zh)

Inventor

钟武

曹诚

曹瑞源

高婷

肖庚富

胡志红

王曼丽

张磊砢

李松

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Institute of Pharmacology and Toxicology of AMMS

Academy of Military Medical Sciences AMMS of PLA

Original Assignee

Institute of Pharmacology and Toxicology of AMMS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2020-01-21

Filing date

2020-01-21

Publication date

2020-06-12

2020-01-21 Priority to CN202010070142.0A priority Critical patent/CN111265528A/zh

2020-01-21 Application filed by Institute of Pharmacology and Toxicology of AMMS filed Critical Institute of Pharmacology and Toxicology of AMMS

2020-06-12 Publication of CN111265528A publication Critical patent/CN111265528A/zh

2020-06-22 Priority to PCT/CN2020/097395 priority patent/WO2021147235A1/zh

2020-06-22 Priority to CN202010572752.0A priority patent/CN111557939B/zh

2020-10-12 Priority to TW109135164A priority patent/TWI798593B/zh

2020-10-13 Priority to EA202092168A priority patent/EA202092168A1/ru

2020-10-14 Priority to JP2020173044A priority patent/JP2021116296A/ja

2020-10-14 Priority to US17/070,620 priority patent/US20210220353A1/en

2020-10-16 Priority to EP20202257.0A priority patent/EP3854398A1/en

2021-01-20 Priority to UY0001039027A priority patent/UY39027A/es

2021-07-16 Priority to US17/378,361 priority patent/US11318135B2/en

2023-11-02 Priority to JP2023188351A priority patent/JP2024003097A/ja

Status Pending legal-status Critical Current

Links

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses

CN202010070142.0A 2020-01-21 2020-01-21 法匹拉韦在治疗冠状病毒感染方面的应用 Pending CN111265528A (zh)

Priority Applications (11)

Application Number	Priority Date	Filing Date	Title
CN202010070142.0A CN111265528A (zh)	2020-01-21	2020-01-21	法匹拉韦在治疗冠状病毒感染方面的应用
PCT/CN2020/097395 WO2021147235A1 (zh)	2020-01-21	2020-06-22	法匹拉韦在治疗冠状病毒感染方面的应用
CN202010572752.0A CN111557939B (zh)	2020-01-21	2020-06-22	法匹拉韦在制备用于治疗冠状病毒感染的药物中的应用
TW109135164A TWI798593B (zh)	2020-01-21	2020-10-12	法匹拉韋在治療冠狀病毒感染方面的應用
EA202092168A EA202092168A1 (ru)	2020-01-21	2020-10-13	Применение фавипиравира в лечении коронавирусной инфекции
JP2020173044A JP2021116296A (ja)	2020-01-21	2020-10-14	コロナウイルス感染の治療におけるファビピラビルの使用
US17/070,620 US20210220353A1 (en)	2020-01-21	2020-10-14	Use of favipiravir in treatment of coronavirus infection
EP20202257.0A EP3854398A1 (en)	2020-01-21	2020-10-16	Use of favipiravir in the treatment of coronavirus infection
UY0001039027A UY39027A (es)	2020-01-21	2021-01-20	Uso de favipiravir en el tratamiento de la infección por coronavirus
US17/378,361 US11318135B2 (en)	2020-01-21	2021-07-16	Use of Favipiravir in treatment of coronavirus infection
JP2023188351A JP2024003097A (ja)	2020-01-21	2023-11-02	コロナウイルス感染の治療におけるファビピラビルの使用

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CN202010070142.0A CN111265528A (zh)	2020-01-21	2020-01-21	法匹拉韦在治疗冠状病毒感染方面的应用

Publications (1)

Publication Number	Publication Date
CN111265528A true CN111265528A (zh)	2020-06-12

Family

ID=70993617

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CN202010070142.0A Pending CN111265528A (zh)	2020-01-21	2020-01-21	法匹拉韦在治疗冠状病毒感染方面的应用
CN202010572752.0A Active CN111557939B (zh)	2020-01-21	2020-06-22	法匹拉韦在制备用于治疗冠状病毒感染的药物中的应用

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CN202010572752.0A Active CN111557939B (zh)	2020-01-21	2020-06-22	法匹拉韦在制备用于治疗冠状病毒感染的药物中的应用

Country Status (8)

Country	Link
US (2)	US20210220353A1 (ru)
EP (1)	EP3854398A1 (ru)
JP (2)	JP2021116296A (ru)
CN (2)	CN111265528A (ru)
EA (1)	EA202092168A1 (ru)
TW (1)	TWI798593B (ru)
UY (1)	UY39027A (ru)
WO (1)	WO2021147235A1 (ru)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN111875550A (zh) *	2020-07-24	2020-11-03	内蒙古京东药业有限公司	法匹拉韦二甲基亚砜溶剂化物的晶型及制备方法
CN112353951A (zh) *	2020-07-24	2021-02-12	北京大学	新型冠状病毒动物模型及应用
WO2021147235A1 (zh) *	2020-01-21	2021-07-29	中国人民解放军军事科学院军事医学研究院	法匹拉韦在治疗冠状病毒感染方面的应用
WO2021200651A1 (ja) *	2020-03-30	2021-10-07	富士フイルム富山化学株式会社	コロナウイルス感染症治療剤
CN114053394A (zh) *	2020-07-30	2022-02-18	广州朗圣药业有限公司	新型化合物在制备预防和/或治疗冠状病毒感染的药物中的应用
CN116942665A (zh) *	2023-09-21	2023-10-27	广州市朝利良生物科技有限公司	Kappa阿片受体拮抗剂在制备抗冠状病毒药物中的应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11446320B1 (en)	2021-10-04	2022-09-20	Feynman Labs, LLC	Pharmaceutical combination having potent antiviral activity against single-stranded RNA viruses
WO2023059363A1 (en) *	2021-10-04	2023-04-13	AiPharma Global Holdings LLC	Pharmaceutical combination having potent antiviral activity against single-stranded rna viruses
WO2023059362A1 (en) *	2021-10-06	2023-04-13	AiPharma Global Holdings LLC	Drug and diagnostic combination system to identify and treat single-stranded rna viruses including coronaviruses
CN114246870B (zh) *	2021-12-21	2023-08-01	广东药科大学	MIL-101(Fe)-T705及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0108374B8 (pt) *	2000-02-16	2021-05-25	Fujifilm Toyama Chemical Co Ltd	derivado de pirazina ou um sal deste e composição farmacêutica
EP2407166B1 (en)	2009-03-13	2013-08-21	Toyama Chemical Co., Ltd.	Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide
KR20120093955A (ko) *	2009-10-14	2012-08-23	젬머스 파마 인코포레이티드	바이러스 감염에 대한 병용 요법 치료
WO2013180149A1 (ja) *	2012-05-30	2013-12-05	富山化学工業株式会社	重水素化含窒素複素環カルボキサミド誘導体またはその塩
WO2015173701A2 (en) *	2014-05-12	2015-11-19	Glaxosmithkline Intellectual Property (No. 2) Limited	Pharmaceutical compositions for treating infectious diseases
CN107737128A (zh) *	2017-10-23	2018-02-27	威海贯标信息科技有限公司	一种法匹拉韦片剂组合物
US20220160682A1 (en)	2019-04-04	2022-05-26	Tarsus Pharmaceuticals, Inc.	Systemic isoxazoline parasiticides for vector-borne and viral disease treatment or prophylaxis
BR112021026410A2 (pt)	2019-07-01	2022-02-08	Tonix Pharma Ltd	Anticorpos anti-cd154 e usos dos mesmos
WO2021007283A1 (en) *	2019-07-09	2021-01-14	Regents Of The University Of Minnesota	Potentiation of antiviral nucleobases as rna virus therapy
CA3152665A1 (en)	2019-08-27	2021-03-04	Tonix Pharma Limited	Modified tff2 polypeptides
CN111265528A (zh) *	2020-01-21	2020-06-12	中国人民解放军军事科学院军事医学研究院	法匹拉韦在治疗冠状病毒感染方面的应用
CN111265532A (zh)	2020-01-21	2020-06-12	中国人民解放军军事科学院军事医学研究院	取代氨基丙酸酯类化合物在治疗2019-nCoV感染中的应用

2020
- 2020-01-21 CN CN202010070142.0A patent/CN111265528A/zh active Pending
- 2020-06-22 CN CN202010572752.0A patent/CN111557939B/zh active Active
- 2020-06-22 WO PCT/CN2020/097395 patent/WO2021147235A1/zh active Application Filing
- 2020-10-12 TW TW109135164A patent/TWI798593B/zh active
- 2020-10-13 EA EA202092168A patent/EA202092168A1/ru unknown
- 2020-10-14 US US17/070,620 patent/US20210220353A1/en not_active Abandoned
- 2020-10-14 JP JP2020173044A patent/JP2021116296A/ja active Pending
- 2020-10-16 EP EP20202257.0A patent/EP3854398A1/en active Pending
2021
- 2021-01-20 UY UY0001039027A patent/UY39027A/es unknown
- 2021-07-16 US US17/378,361 patent/US11318135B2/en active Active
2023
- 2023-11-02 JP JP2023188351A patent/JP2024003097A/ja active Pending

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2021147235A1 (zh) *	2020-01-21	2021-07-29	中国人民解放军军事科学院军事医学研究院	法匹拉韦在治疗冠状病毒感染方面的应用
US11318135B2 (en)	2020-01-21	2022-05-03	Academy Of Military Medical Sciences	Use of Favipiravir in treatment of coronavirus infection
WO2021200651A1 (ja) *	2020-03-30	2021-10-07	富士フイルム富山化学株式会社	コロナウイルス感染症治療剤
CN111875550A (zh) *	2020-07-24	2020-11-03	内蒙古京东药业有限公司	法匹拉韦二甲基亚砜溶剂化物的晶型及制备方法
CN112353951A (zh) *	2020-07-24	2021-02-12	北京大学	新型冠状病毒动物模型及应用
CN111875550B (zh) *	2020-07-24	2023-06-06	内蒙古京东药业有限公司	法匹拉韦二甲基亚砜溶剂化物的晶型及制备方法
CN114053394A (zh) *	2020-07-30	2022-02-18	广州朗圣药业有限公司	新型化合物在制备预防和/或治疗冠状病毒感染的药物中的应用
CN116942665A (zh) *	2023-09-21	2023-10-27	广州市朝利良生物科技有限公司	Kappa阿片受体拮抗剂在制备抗冠状病毒药物中的应用
CN116942665B (zh) *	2023-09-21	2023-12-12	广州市朝利良生物科技有限公司	Kappa阿片受体拮抗剂在制备抗冠状病毒药物中的应用

Also Published As

Publication number	Publication date
TWI798593B (zh)	2023-04-11
US11318135B2 (en)	2022-05-03
WO2021147235A1 (zh)	2021-07-29
JP2021116296A (ja)	2021-08-10
US20210346376A1 (en)	2021-11-11
CN111557939B (zh)	2021-05-04
JP2024003097A (ja)	2024-01-11
TW202128168A (zh)	2021-08-01
US20210220353A1 (en)	2021-07-22
CN111557939A (zh)	2020-08-21
EA202092168A1 (ru)	2021-07-30
EP3854398A1 (en)	2021-07-28
UY39027A (es)	2021-03-26

Legal Events

Date	Code	Title	Description
2020-06-12	PB01	Publication
2020-06-12	PB01	Publication
2020-07-07	SE01	Entry into force of request for substantive examination
2020-07-07	SE01	Entry into force of request for substantive examination
2020-08-14	WD01	Invention patent application deemed withdrawn after publication
2020-08-14	WD01	Invention patent application deemed withdrawn after publication	Application publication date: 20200612

Publication	Publication Date	Title
CN111265528A (zh)	2020-06-12	法匹拉韦在治疗冠状病毒感染方面的应用
CN111265532A (zh)	2020-06-12	取代氨基丙酸酯类化合物在治疗2019-nCoV感染中的应用
CN113289018B (zh)	2023-08-25	金诺芬等老药及其组合物在抗单正链rna病毒中的应用
CN111743899B (zh)	2021-03-30	硝唑尼特及其活性形式替唑尼特在制备用于治疗SARS-CoV-2感染的药物中的应用
CN111803491A (zh)	2020-10-23	青蒿素类化合物在治疗冠状病毒感染方面的应用
CN113813258B (zh)	2024-04-26	抗rna病毒药物及其应用
JP2023534723A (ja)	2023-08-10	コロナウイルス感染症の治療におけるベンフルメトール及びその誘導体の応用
WO2020259706A1 (zh)	2020-12-30	氨来占诺用于制备抗肝炎病毒药物的用途
CN107536838A (zh)	2018-01-05	硝唑尼特及其活性形式替唑尼特在治疗寨卡病毒感染方面的应用
CN113440527A (zh)	2021-09-28	萘酚喹或含萘酚喹的组合制剂在抗冠状病毒中的应用
CN113262224A (zh)	2021-08-17	奈非那韦在制备防治新冠肺炎药物中的应用
CN113456632B (zh)	2023-09-26	抗rna病毒药物及其应用
CN116687932B (zh)	2024-03-29	((3-氨甲酰-5-氟吡嗪-2-基)氧基)甲基异丁酸酯的医药用途
EP3960173A1 (en)	2022-03-02	Enterovirus inhibitor
CN113456817B (zh)	2024-05-10	抗rna病毒药物的dhodh抑制剂及其应用
CN107714713B (zh)	2020-05-26	台勾霉素衍生物在制备治疗登革病毒感染引起的相关疾病和/或症状的药物中的应用
WO2021155654A1 (zh)	2021-08-12	利托那韦在治疗SARS-CoV-2感染方面的应用